

International Application No. PCT/EP03/06094
International Filing Date: 10 June 2003

Amendments to the claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (original) A multivalent meningococcal bleb composition comprising a bleb preparation deficient in PorA in that it has less than 80% of the amount of PorA as compared to the same quantity of blebs made from strain H44/76 and a bleb preparation that is not deficient in PorA compared to blebs made from strain H44/76.
2. (original) The multivalent meningococcal bleb composition of claim 1, wherein the bleb preparation that is not deficient in PorA is derived from a meningococcal strain with a serosubtype that is prevalent in a country of use.
3. (currently amended) The multivalent meningococcal bleb composition of claim 1 ~~or 2~~, wherein the bleb preparation deficient in PorA has less than 22% PorA of total bleb protein, or lacks PorA.
4. (currently amended) The multivalent meningococcal bleb composition of ~~claims 1-3~~ claim 1, wherein the bleb preparation not deficient in PorA has more than 28% PorA of total bleb protein.
5. (currently amended) The multivalent meningococcal bleb composition of ~~claims 1-4~~ claim 1, wherein the bleb preparation deficient in PorA is derived from the meningococcal CU-385 strain.
6. (currently amended) A vaccine for the treatment of neisserial, preferably meningococcal, disease comprising the multivalent meningococcal bleb composition of ~~claims 1-5~~ claim 1, and a pharmaceutically acceptable excipient.
7. (original) The vaccine of claim 6 additionally comprising one or more plain or conjugated meningococcal capsular polysaccharides selected from the following list of serotypes: A, C, Y and W.

International Application No. PCT/EP03/06094
International Filing Date: 10 June 2003

8. (currently amended) The vaccine of claim 6 ~~or 7~~ suitable for use in New Zealand or Europe wherein the bleb preparation that is not deficient in PorA is derived from a meningococcal strain with a serosubtype of P1.4.

9. (currently amended) The vaccine of claim 6 ~~or 7~~ suitable for use in USA where the bleb preparation that is not deficient in PorA is derived from a meningococcal strain with a serosubtype of P1.7,16.

10. (currently amended) The vaccine of claim 6 ~~or 7~~ suitable for use in Norway wherein the bleb preparation that is not deficient in PorA is derived from a meningococcal strain with a serosubtype of P1.16.

11. (currently amended) A method of manufacturing the multivalent meningococcal bleb composition of ~~claims 1-5~~ claim 1 ~~or the vaccine of claims 6-10~~ comprising the step of combining the bleb preparation that is not deficient in PorA with the bleb preparation that is deficient in PorA.

12. (currently amended) A method of preventing or treating neisserial, preferably meningococcal, disease comprising the step of administering an immunologically effective amount of the vaccine of ~~claims 6-10~~ claim 6 to a host in need thereof.

13. (currently amended) The use of an immunologically effective amount of the vaccine of ~~claims 6-10~~ claim 6 in the manufacture of a medicament for the prevention or treatment of neisserial, preferably meningococcal, disease.

14. (new) A method of manufacturing the vaccine of Claim 6 comprising the step of combining the bleb preparation that is not deficient in PorA with the bleb preparation that is deficient in PorA.